Back to results
US 2021/0023116 A1Published application
Treatment of cancer by systemic administration of dbait molecules
AssigneesOnxeo, Institut Curie, Centre National De La Recherche Scientifique, Institut National de la Sante et de la Recherche Medicale
InventorsMARIE DUTREIX, NATHALIE BERTHAULT
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of a DBait molecules by systemic routes without any combination with an endosomolytic agent.
Claims13
A method of treating ovarian cancer comprising the administration, by a parenteral systemic route selected from intraperitoneal and intravenous administration to a subject having an ovarian cancer, a nucleic acid molecule of the following formula:
- wherein N is a deoxynucleotide, n is an integer from 15 to 195, the underlined N refers to a nucleotide having or not a modified phosphodiester backbone, L′ is a linker, C is the molecule facilitating endocytosis selected from a lipophilic molecule or a ligand which targets cell receptor enabling receptor mediated endocytosis, L is a linker, m is an integer being 0 or 1 and p is 1;
- wherein the nucleic acid is to be used without combined administration of any quinoline endosomolytic agent.
Dependencies are inferred from the claim text.